Drug Trial Radar · NCT04016779
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD
Last checked: Nov 20, 2026Latest source record: Jul 12, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
374
Actual
Start
Nov 20, 2019
Primary completion
Oct 10, 2020
Study completion Oct 10, 2020
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of SPN-812 (Viloxazine extended-release capsules; 200-600 mg) in adults 18-65 years of age with Attention-Deficit/Hyperactivity Disorder (ADHD).
Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
Interventions
PlaceboDrug
Placebo will be administered once daily
SPN-812Drug
SPN-812 will be administered once daily and compared to Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of SPN-812 on Symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) as Assessed by the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total ScoreTime frame: Baseline and Week 6
Locations
37 sites in 1 country. Site status is shown where the registry gives one.
Collaborative Neuroscience Network
Garden Grove, California
Pharmacology Research Institute
Los Alamitos, California
Pharmacology Research Institute
Newport Beach, California
Artemis Research Institute for Clinical Research
Riverside, California
Artemis Institute for Clinical Research
San Diego, California
Artemis Institute for Clinical Research
San Marcos, California
Collaborative Neuroscience Network LLC
Torrance, California
Gulfcoast Research Center
Fort Myers, Florida
Research Centers of America
Hollywood, Florida
Clinical Neuroscience Solutions, Inc
Jacksonville, Florida
Meridien Research
Lakeland, Florida
Medical Research Group of Central Florida
Orange City, Florida
Clinical Neuroscience Solutions Inc.
Orlando, Florida
CNS Healthcare
Orlando, Florida
Meridien Research
Tampa, Florida
Atlanta Center for Medical Research
Atlanta, Georgia
iResearch Atlanta
Decatur, Georgia
Psych Atlanta
Marietta, Georgia
Psychiatric Associates
Overland Park, Kansas
St. Charles Psychiatric Associates Midwest Research Center
Saint Charles, Missouri
Alivation Research, LLC
Lincoln, Nebraska
Altea Research Institute
Las Vegas, Nevada
Center for Psychiatry and Behavioral Medicine, Inc.
Las Vegas, Nevada
Hassman Research Institute
Berlin, New Jersey
Center for Emotional Fitness
Cherry Hill, New Jersey
Hassmann Research Institute
Marlton, New Jersey
Princeton Medical Institute
Princeton, New Jersey
Bioscience Research
Mount Kisco, New York
The Medical Research Network LLC
New York, New York
Paradigm Research Professionals
Oklahoma City, Oklahoma
CNS Healthcare
Memphis, Tennessee
BioBehavioral Research of Austin P.C.
Austin, Texas
FutureSearch Trials of Dallas, LLP
Dallas, Texas
Houston Clinical Trials
Houston, Texas
Family Psychiatry of the Woodlands
The Woodlands, Texas
Ericksen Research & Development
Clinton, Utah
Northwest Clinical Trials
Bellevue, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.